Biotech | April 06, 2026
Enveda’s experimental oral therapy shows breakthrough results in atopic dermatitis trial
Safety was equally impressive. ENV-294 was well tolerated
Safety was equally impressive. ENV-294 was well tolerated
In his new role, Saran will spearhead the end-to-end launch framework for innovation-led portfolio
With more than two decades of experience, he brings deep expertise in sales, marketing, business transformation, and strategic leadership
They also differentiated the innovator biologic Semaglutide molecule from newer synthetic or chemical generic versions entering the market
Institute signs four MoUs, launches two products and marks 75 years with renewed focus on lab-to-market commercialisation
Minister highlights scope for domestic manufacturing during his meeting with Dr Niti Pall, President-elect, International Diabetes Federation
The record-setting effort stems from Danone India’s nationwide ‘IRON UP!’ campaign
The deal gives Cupid immediate access to Style Baazar’s fast-growing network of over 260 stores
The JADE trial enrolled 164 U.S. patients who initially received three monthly doses of OLN324 or faricimab, followed by 12 weeks off treatment with retreatment allowed only if disease recurred
ANDA approval for 100 mg and 150 mg capsules targeting idiopathic pulmonary fibrosis opens access to a $3.76 billion market in USA
Subscribe To Our Newsletter & Stay Updated
